Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
The Growing Role of Monoclonal Antibodies in Relapsed/Refractory Follicular Lymp...
Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.
Immunotherapy Is on the Cusp of Major Breakthroughs in Multiple Myeloma
Just a decade ago, immune therapy for multiple myeloma barely existed as an idea. Since then, immune therapy has evolved rapidly and the field is on the verge of major improvements in outcomes.
Brentuximab Vedotin Plus Chemotherapy Works as a Primary Option for Hodgkin Lymp...
Pierluigi Porcu, MD, explained how the combination of brentuximab vedotin plus chemotherapy works in in frontline setting of Hodgkin lymphoma during a virtual Targeted Oncology Case-Based Roundtable event.
Zelenoleucel in Phase 2 Study of Patients With AML
The first patient with acute myeloid leukemia in a phase 2 trial of the MultiTAA-specific T cell, MT-401 followed stem-cell transplant has been dosed with the agent, according to a press release by Marker Therapeutics, Inc.
Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.
Early Successes and Remaining Challenges of Harnessing Natural Killer Cells for ...
Natural killer cells can offer several advantages over T cells for CAR therapy in that the former uses both a CAR dependent and independent mechanism for tumor eradication, has better safety, and off-the-shelf feasibility—all at a potentially lower cost.
Relapsed/Refractory DLBCL Undergoes Rapid Evolution With CAR T-Cell Therapy, ADC...
High-dose chemotherapy and transplant remains the second-line standard of care for the majority of patients with relapsed/refractory diffuse large B-cell lymphoma; however, CAR T-cell therapy and other novel agents, which have transformed the third-line setting, may offer alternative and more personalized second-line options in the coming years.
Cirmtuzumab/Ibrutinib Shows Encouraging Clinical Activity, Safety in MCL and CLL
Hun Ju Lee, MD, discusses a phase 1/2 study evaluating cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma or chronic lymphocytic leukemia.
Ianalumab/Ibrutinib Combo Shows Promising Activity in CLL
Kerry A, Rogers, MD, discusses the rationale behind the phase 1b study of VAY736 combined with ibrutinib in patients with chronic lymphocytic leukemia and the next steps for this research.
Multi-Agent Therapy May Overcome CAR T Resistance in B-Cell Malignancies
Treatment with chimeric antigen receptor T-cells has induced unprecedented overall response rates and complete response rates in patients with relapsed/refractory B cell malignancies.